Synergistic effect of aminoguanidine and l-carnosine against thioacetamide-induced hepatic encephalopathy in rats : behavioral, biochemical, and ultrastructural evidence
Hepatic encephalopathy depicts the cluster of neurological alterations that occur during acute or chronic hepatic injury. Hyperammonemia, inflammatory injury, and oxidative stress are the main predisposing factors for the direct and indirect changes in cerebral metabolism causing encephalopathy. The aim of this study was to evaluate the possible synergistic effect between aminoguanidine (AG; 100 mg/kg, p.o.) and l-carnosine (CAR; 200 mg/kg, p.o.) on hepatic encephalopathy that was induced by thioacetamide (TAA; 100 mg/kg, i.p.) administered three times weekly for six weeks. Behavioral changes, biochemical parameters, histopathological analysis, and immunohistochemical and ultrastructural studies were conducted 24 h after the last treatment. Combining AG with CAR improved TAA-induced locomotor impairment and motor incoordination evidenced by reduced locomotor activity and decline in motor skill performance, as well as ameliorated cognitive deficits. Moreover, both drugs restored the levels of serum hepatic enzymes and serum and brain levels of ammonia. In addition, the combination significantly modulated hepatic and brain oxidative stress biomarkers, inflammatory cytokines, and cleaved caspase-3 expression. Furthermore, they succeeded in activating nuclear erythroid 2-related factor 2 (Nrf2) expression and heme oxygenase-1 (HO-1) activity and ameliorating markers of hepatic encephalopathy, including hepatic necrosis and brain astrocyte swelling. This study shows that combining AG with CAR exerted a new intervention for hepatic and brain damage in hepatic encephalopathy due to their complementary antioxidant, anti-inflammatory effects and hypoammonemic effects via Nrf2/HO-1 activation and NO inhibition.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:99 |
|---|---|
| Enthalten in: |
Canadian journal of physiology and pharmacology - 99(2021), 3 vom: 24. März, Seite 332-347 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Afifi, Nehal A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.03.2021 Date Revised 22.03.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1139/cjpp-2020-0212 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312969805 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312969805 | ||
| 003 | DE-627 | ||
| 005 | 20231225145549.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1139/cjpp-2020-0212 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1043.xml |
| 035 | |a (DE-627)NLM312969805 | ||
| 035 | |a (NLM)32721224 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Afifi, Nehal A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Synergistic effect of aminoguanidine and l-carnosine against thioacetamide-induced hepatic encephalopathy in rats |b behavioral, biochemical, and ultrastructural evidence |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.03.2021 | ||
| 500 | |a Date Revised 22.03.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Hepatic encephalopathy depicts the cluster of neurological alterations that occur during acute or chronic hepatic injury. Hyperammonemia, inflammatory injury, and oxidative stress are the main predisposing factors for the direct and indirect changes in cerebral metabolism causing encephalopathy. The aim of this study was to evaluate the possible synergistic effect between aminoguanidine (AG; 100 mg/kg, p.o.) and l-carnosine (CAR; 200 mg/kg, p.o.) on hepatic encephalopathy that was induced by thioacetamide (TAA; 100 mg/kg, i.p.) administered three times weekly for six weeks. Behavioral changes, biochemical parameters, histopathological analysis, and immunohistochemical and ultrastructural studies were conducted 24 h after the last treatment. Combining AG with CAR improved TAA-induced locomotor impairment and motor incoordination evidenced by reduced locomotor activity and decline in motor skill performance, as well as ameliorated cognitive deficits. Moreover, both drugs restored the levels of serum hepatic enzymes and serum and brain levels of ammonia. In addition, the combination significantly modulated hepatic and brain oxidative stress biomarkers, inflammatory cytokines, and cleaved caspase-3 expression. Furthermore, they succeeded in activating nuclear erythroid 2-related factor 2 (Nrf2) expression and heme oxygenase-1 (HO-1) activity and ameliorating markers of hepatic encephalopathy, including hepatic necrosis and brain astrocyte swelling. This study shows that combining AG with CAR exerted a new intervention for hepatic and brain damage in hepatic encephalopathy due to their complementary antioxidant, anti-inflammatory effects and hypoammonemic effects via Nrf2/HO-1 activation and NO inhibition | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Nrf2 activator | |
| 650 | 4 | |a activateur de Nrf2 | |
| 650 | 4 | |a aminoguanidine | |
| 650 | 4 | |a carnosine | |
| 650 | 4 | |a encéphalopathie hépatique | |
| 650 | 4 | |a heme oxygenase-1 | |
| 650 | 4 | |a hepatic encephalopathy | |
| 650 | 4 | |a hème oxygénase-1 | |
| 650 | 7 | |a Guanidines |2 NLM | |
| 650 | 7 | |a Thioacetamide |2 NLM | |
| 650 | 7 | |a 075T165X8M |2 NLM | |
| 650 | 7 | |a Ammonia |2 NLM | |
| 650 | 7 | |a 7664-41-7 |2 NLM | |
| 650 | 7 | |a Carnosine |2 NLM | |
| 650 | 7 | |a 8HO6PVN24W |2 NLM | |
| 650 | 7 | |a pimagedine |2 NLM | |
| 650 | 7 | |a SCQ4EZQ113 |2 NLM | |
| 700 | 1 | |a Ramadan, A |e verfasserin |4 aut | |
| 700 | 1 | |a Erian, Emad Y |e verfasserin |4 aut | |
| 700 | 1 | |a Sedik, Ahmed A |e verfasserin |4 aut | |
| 700 | 1 | |a Amin, Mohamed M |e verfasserin |4 aut | |
| 700 | 1 | |a Hassan, Azza |e verfasserin |4 aut | |
| 700 | 1 | |a Saleh, Dalia O |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Canadian journal of physiology and pharmacology |d 1964 |g 99(2021), 3 vom: 24. März, Seite 332-347 |w (DE-627)NLM000001635 |x 1205-7541 |7 nnns |
| 773 | 1 | 8 | |g volume:99 |g year:2021 |g number:3 |g day:24 |g month:03 |g pages:332-347 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1139/cjpp-2020-0212 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 99 |j 2021 |e 3 |b 24 |c 03 |h 332-347 | ||